AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 241 min read$STX

Romano Gianluca sold $7.7M of STX

Romano Gianluca (EVP & CFO) sold 9,076 shares of Seagate Technology Holdings plc (STX) at $849.35 ($7.71M total) across 3 trades on 2026-08-21.

Original reporting
SEC EDGAR · Romano Gianluca
Published Aug 24, 2026, 9:10 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 24, 2026, 9:15 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$STX
Neutral
medium confidence
Mentioned
$STX
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STXNeutralLow
01

Why it matters

The transaction provides fresh data on insider sentiment, useful for short‑term risk assessment.

02

Market read

Insider sales are closely watched; this filing adds a new data point for STX traders.

03

What to watch

Potential upcoming compensation package or tax planning could explain the timing.

Relevance 6/10Novelty 8/10Timing: post‑market filing on 2026‑08‑24

Background

SEC Form 4 filings disclose insider transactions; this filing reports a CFO‑level sale.

Company-level read

Ticker impact

$STXNeutralMedium confidence
Context

CFO Romano Gianluca sold 9,076 shares for $7.7M in an open‑market Form 4 filing.

Expected impact

Potential short‑term pressure on STX price, likely limited to a few basis points.

Evidence & confidence

A $7.7M sale by the CFO is material enough to attract attention, yet the share count represents a small fraction of total float.

Market effects

Sector

Minimal impact on the broader data‑storage sector; insider sales are company‑specific.

Regional

No discernible regional effect.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

The sale could be routine diversification rather than a negative signal.

Key entities

  • Company
    Seagate Technology Holdings plc

    Data storage hardware manufacturer listed on NYSE under ticker STX.

  • Executive
    Romano Gianluca

    Executive Vice President & Chief Financial Officer of Seagate.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

STX insider trading history →

Related articles

AUG 28
$NVDAHighAI 9/10

Markets News, Aug. 27, 2026: Nvidia Stock Powers Higher After Earnings, Driving Tech Gains; Nasdaq Closes Sharply Higher

Nvidia (NVDA) reported strong Q2 earnings and raised Q3 revenue guidance to $108B, driving its stock up 9% and boosting tech sector gains. Nasdaq, S&P 500, and Dow closed higher. Other notable movers include Okta (OKTA) +29%, Salesforce (CRM) +23%, and CrowdStrike (CRWD) +20%. Corporate profits surged $400B in Q2, partly due to $71B in tariff refunds.

yahoo.com3 min
AUG 28
$STXMed

Moody’s upgrades Seagate Data rating on AI demand strength

Moody's upgraded Seagate Data's corporate family rating to Ba1 from Ba2, citing AI-driven demand for high-capacity HDDs. The agency expects revenues to grow over 30% annually, reaching $20B, and debt to EBITDA to fall below 0.5x. Seagate faces risks from revenue concentration and pricing pressures. The company had $1.7B in cash and access to a $1.3B credit facility as of July 2026.

investing.com2 min
AUG 27
$MRNAHighAI 8/10

3 Stocks Soared, 3 Stocks Slumped

Moderna (MRNA) surged 176.97% to $174.38 after reporting positive trial results for a cancer therapy with Merck (MRK). Estee Lauder (EL) rose 16% to $98.01 with revenue up 6.5% Y/Y. MicroStrategy (MSTR) gained 12.68% as Bitcoin prices rose. Nebius (NBIS) fell 10% after a $4.5B convertible note offering. Seagate (STX) dropped 8% to $832.56.

baystreet.ca2 min
AUG 27
$STXMed

REG - Shield Therapeutics - Shield assumes full control of ACCRUFeR® in the US

Shield Therapeutics (STX) will take full control of ACCRUFeR® in the US from Viatris by September 30, 2026. The deal is expected to boost Shield's profitability and growth, with no upfront payments to Viatris. Shield will pay royalties on US net sales, ranging from high single digits to mid-teens over five years, and retain all gross profits from US sales. The transaction is anticipated to enhance Shield's financial profile and support its path to sustained profitability.

tradingview.com2 min